Increased tumor vascularization is associated with the amount of immune competent PD-1 positive cells in testicular germ cell tumors

Testicular germ cell cancer in a metastatic state is curable with a cisplatin‑based first line chemotherapy. However, 10‑15% of these patients are resistant to first line chemotherapy and are thus left with only palliati
Testicular germ cell cancer in a metastatic state is curable with a cisplatin‑based first line chemotherapy. However, 10‑15% of these patients are resistant to first line chemotherapy and are thus left with only palliative options. Immunotherapies and inhibition of angiogenesis used in multiple types of cancer; however, the molecular context of angiogenesis and immune checkpoints in the development and progression of testicular cancers is still unknown. Therefore, the present study performed tissue micro array based analysis of 84 patients with immunohistochemistry of programmed cell death protein 1 (PD‑1), programmed cell death ligand 1 (PD‑L1) and vascular endothelial growth factor receptor 2 (VEGFR2) of testicular cancer and corresponding normal appearing testis tissue, matching the results with clinical data. The results demonstrated that PD‑L1 was significantly upregulated in testicular tumors and that PD‑1 positive cells significantly infiltrated the testicular tumor when compared with normal testicular tissue. VEGFR2 was significantly upregulated in testicular cancer. It was indicated that PD‑1 expressing cytotoxic cells may require pathologic tumor vessels to pass the blood‑testis‑barrier in order to migrate into the tumor. Notably, when matching the clinical data for PD‑1, PD‑L1 and VEGFR2 there were no differences in expression in the different International Germ Cell Cancer Collaborative Group stages of non‑seminoma. These data suggested that the anti‑PD‑1/PD‑L1 immunotherapy and the anti‑angiogenic therapy, sequentially or in combination, may be a promising option in the treatment of testicular cancer.
show moreshow less

Metadaten
Author:Lukas Jennewein, Georg Bartsch, Kilian Gust, Hans-Michael Kvasnicka, Axel Haferkamp, Roman A. Blaheta, Michel Guy André Mittelbronn, Patrick Nikolaus Harter, Jens Mani
URN:urn:nbn:de:hebis:30:3-468532
DOI:http://dx.doi.org/10.3892/ol.2018.8597
ISSN:1792-1082
ISSN:1792-1074
Pubmed Id:http://www.ncbi.nlm.nih.gov/pubmed?term=29928359
Parent Title (English):Oncology letters
Publisher:Spandidos Publ.
Place of publication:Athens
Document Type:Article
Language:English
Year of Completion:2018
Date of first Publication:2018/04/27
Publishing Institution:Universitätsbibliothek Johann Christian Senckenberg
Release Date:2018/07/05
Tag:immune; programmed cell death ligand 1; programmed cell death protein 1; testicular cancer; vascular endothelial growth factor receptor 2
Volume:15
Issue:6
Pagenumber:9
First Page:9852
Last Page:9860
Note:
Copyright: © Jennewein et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
HeBIS PPN:435733516
Institutes:Medizin
Dewey Decimal Classification:610 Medizin und Gesundheit
Sammlungen:Universitätspublikationen
Licence (German):License LogoCreative Commons - Namensnennung-Nicht kommerziell - Keine Bearbeitung 4.0

$Rev: 11761 $